Emerging approaches in predictive toxicology

Environmental and Molecular Mutagenesis

Volumn 55, Issue 9, 2014, Pages 679-688

  Zhang, Luoping ^a   Mchale, Cliona M ^a   Greene, Nigel ^b   Snyder, Ronald D ^c   Rich, Ivan N ^d   Aardema, Marilyn J ^e,f   Roy, Shambhu ^f   Pfuhler, Stefan ^g   Venkatactahalam, Sundaresan ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PFIZER INC   (United States)

^c RDS Consulting Services   (United States)

^d Hemogenix   (United States)

^e Marilyn Aardema Consulting   (United States)

^f BioReliance Corporation   (United States)

^g PROCTER AND GAMBLE COMPANY   (United States)

^h NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Genotoxicity; in silico approaches; Model systems; Predictive toxicology

Indexed keywords

ANIMAL; CHICKEN; COMPUTER SIMULATION; DNA REPAIR; DRUG EFFECTS; GENETICS; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; LYMPHOCYTE; MUTAGEN TESTING; PROCEDURES; STEM CELL; THEORETICAL MODEL; TOXICOLOGY; YEAST;

ANIMALS; CHICKENS; COMPUTER SIMULATION; DNA REPAIR; GENOMICS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LYMPHOCYTES; MODELS, THEORETICAL; MUTAGENICITY TESTS; STEM CELLS; TOXICOLOGY; YEASTS;

EID: 84912141036     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.21885     Document Type: Note

References (59)

1. Aardema MJ, Barnett BC, Khambatta Z, Reisinger K, Ouedraogo-Arras G, Faquet B, Ginestet AC, Mun GC, Dahl EL, Hewitt NJ, et al. 2010. International prevalidation studies of the EpiDerm 3D human reconstructed skin micronucleus [RSMN] assay: transferability and reproducibility. Mutat Res 701:123-131.
2. Aardema MJ, Barnett BB, Mun GC, Dahl EL, Curren RD, Hewitt NJ, Pfuhler S. 2013. Evaluation of chemicals requiring metabolic activation in the EpiDerm 3D human reconstructed skin micronucleus [RSMN] assay. Mutat Res 750:40-49.
3. Aksoy I, Stanton LW. 2013. Pluripotency-regulating networks provide basis for reprogramming. Curr Mol Med 13:695-706.
4. Aldridge JE, Gibbons JA, Flaherty MM, Kreider ML, Romano JA, Levin ED. 2003. Heterogeneity of toxicant response: sources of human variability. Toxicol Sci 76:3-20.
5. Ames BN, McCann J, Yamasaki E. 1975. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat Res 31:347-364.
6. Ashby J, Tennant RW, Zeiger E, Stasiewicz S. 1989. Classification according to chemical structure, mutagenicity to Salmonella and level of carcinogenicity of a further 42 chemicals tested for carcinogenicity by the U.S. National Toxicology Program. Mutat Res 223:73-103.
7. Buerstedde JM, Takeda S. 1991. Increased ratio of targeted to random integration after transfection of chicken B cell lines. Cell 67:179-188.
8. Carette JE, Guimaraes CP, Varadarajan M, Park AS, Wuethrich I, Godarova A, Kotecki M, Cochran BH, Spooner E, Ploegh HL, et al. 2009. Haploid genetic screens in human cells identify host factors used by pathogens. Science 326:1231-1235.
9. Curren RD, Mun GC, Gibson DP, Aardema MJ. 2006. Development of a method for assessing micronucleus induction in a 3D human skin model [EpiDerm]. Mutat Res 607:192-204.
10. Dahl EL, Curren R, Barnett BC, Khambatta Z, Reisinger K, Ouedraogo G, Faquet B, Ginestet AC, Mun G, Hewitt NJ, et al. 2011. The reconstructed skin micronucleus assay [RSMN] in EpiDerm: detailed protocol and harmonized scoring atlas. Mutat Res 720:42-52.
11. de Graaf B, Clore A, McCullough AK. 2009. Cellular pathways for DNA repair and damage tolerance of formaldehyde-induced DNA-protein crosslinks. DNA Repair [Amst] 8:1207-1214.
12. Dorne JL. 2009. Metabolism, variability and risk assessment. Toxicology 268:156-164.
13. Elling U, Taubenschmid J, Wirnsberger G, O'Malley R, Demers SP, Vanhaelen Q, Shukalyuk AI, Schmauss G, Schramek D, Schnuetgen F, et al. 2011. Forward and reverse genetics through derivation of haploid mouse embryonic stem cells. Cell Stem Cell 9:563-574.
14. Evans TJ, Yamamoto KN, Hirota K, Takeda S. 2010. Mutant cells defective in DNA repair pathways provide a sensitive high-throughput assay for genotoxicity. DNA Repair [Amst] 9:1292-1298.
15. Ferguson LR, Denny WA. 2007. Genotoxicity of non-covalent interactions: DNA intercalators. Mutat Res 623:14-23.
16. Galvan N, Lim S, Zmugg S, Smith MT, Zhang L. 2008. Depletion of WRN enhances DNA damage in HeLa cells exposed to the benzene metabolite, hydroquinone. Mutat Res 649:54-61.
17. Guyton KZ, Kyle AD, Aubrecht J, Cogliano VJ, Eastmond DA, Jackson M, Keshava N, Sandy MS, Sonawane B, Zhang L, et al. 2009. Improving prediction of chemical carcinogenicity by considering multiple mechanisms and applying toxicogenomic approaches. Mutat Res 681:230-240.
18. Harari F, Engstrom K, Concha G, Colque G, Vahter M, Broberg K. 2013. N-6-adenine-specific DNA methyltransferase 1 [N6AMT1] polymorphisms and arsenic methylation in Andean women. Environ Health Perspect 121:797-803.
19. Harper H, Rich IN. 2013. Stem cell predictive hemotoxicology. In: Alimoghaddam K, editor. Stem Cell Biology in Normal Life and Diseases: InTech, Rijeka, Croatia.
20. Hendry LB, Mahesh VB, Bransome ED Jr, Ewing DE. 2007. Small molecule intercalation with double stranded DNA: implications for normal gene regulation and for predicting the biological efficacy and genotoxicity of drugs and other chemicals. Mutat Res 623:53-71.
21. Hoffmann GR, Gessner GS, Hughes JF, Ronan MV, Sylvia KE, Willett CJ. 2007. Modulation of the genotoxicity of bleomycin by amines through noncovalent DNA interactions and alteration of physiological conditions in yeast. Mutat Res 623:41-52.
22. Hu T, Kaluzhny Y, Mun GC, Barnett B, Karetsky V, Wilt N, Klausner M, Curren RD, Aardema MJ. 2009. Intralaboratory and interlaboratory evaluation of the EpiDerm 3D human reconstructed skin micronucleus [RSMN] assay. Mutat Res 673:100-108.
23. Ji K, Kogame T, Choi K, Wang X, Lee J, Taniguchi Y, Takeda S. 2009. A novel approach using DNA-repair-deficient chicken DT40 cell lines for screening and characterizing the genotoxicity of environmental contaminants. Environ Health Perspect 117:1737-1744.
24. Jo WJ, Loguinov A, Wintz H, Chang M, Smith AH, Kalman D, Zhang L, Smith MT, Vulpe CD. 2009a. Comparative functional genomic analysis identifies distinct and overlapping sets of genes required for resistance to monomethylarsonous acid [MMAIII] and arsenite [AsIII] in yeast. Toxicol Sci 111:424-436.
25. Jo WJ, Ren X, Chu F, Aleshin M, Wintz H, Burlingame A, Smith MT, Vulpe CD, Zhang L. 2009b. Acetylated H4K16 by MYST1 protects UROtsa cells from arsenic toxicity and is decreased following chronic arsenic exposure. Toxicol Appl Pharmacol 241:294-302.
26. Kola I, Landis J. 2004. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715.
27. Lan Q, Zhang L, Shen M, Jo WJ, Vermeulen R, Li G, Vulpe C, Lim S, Ren X, Rappaport SM, et al. 2009. Large-scale evaluation of candidate genes identifies associations between DNA repair and genomic maintenance and development of benzene hematotoxicity. Carcinogenesis 30:50-58.
28. Leeb M, Wutz A. 2011. Derivation of haploid embryonic stem cells from mouse embryos. Nature 479:131-134.
29. Leeb M, Walker R, Mansfield B, Nichols J, Smith A, Wutz A. 2012. Germline potential of parthenogenetic haploid mouse embryonic stem cells. Development 139:3301-3305.
30. Li W, Shuai L, Wan H, Dong M, Wang M, Sang L, Feng C, Luo GZ, Li T, Li X, et al. 2012. Androgenetic haploid embryonic stem cells produce live transgenic mice. Nature 490:407-411.
31. Mahajan R, Gupta K. 2010. Food and drug administration's critical path initiative and innovations in drug development paradigm: Challenges, progress, and controversies. J Pharm Bioallied Sci 2:307-313.
32. Mun GC, Aardema MJ, Hu T, Barnett B, Kaluzhny Y, Klausner M, Karetsky V, Dahl EL, Curren RD. 2009. Further development of the EpiDerm 3D reconstructed human skin micronucleus [RSMN] assay. Mutat Res 673:92-99.
33. Naven RT, Greene N, Williams RV. 2012. Latest advances in computational genotoxicity prediction. Expert Opin Drug Metab Toxicol 8:1579-1587.
34. Nelson SM, Ferguson LR, Denny WA. 2007. Non-covalent ligand/DNA interactions: minor groove binding agents. Mutat Res 623:24-40.
35. North M, Vulpe CD. 2010. Functional toxicogenomics: mechanism-centered toxicology. Int J Mol Sci 11:4796-4813.
36. North M, Tandon VJ, Thomas R, Loguinov A, Gerlovina I, Hubbard AE, Zhang L, Smith MT, Vulpe CD. 2011. Genome-wide functional profiling reveals genes required for tolerance to benzene metabolites in yeast. PLoS One 6:e24205.
37. North M, Shuga J, Fromowitz M, Shannon KM, Zhang L, Smith MT, Vulpe CD. 2014. Modulation of ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke. BMC Cancer 14:6.
38. Olaharski AJ, Uppal H, Cooper M, Platz S, Zabka TS, Kolaja KL. 2009. In vitro to in vivo concordance of a high throughput assay of bone marrow toxicity across a diverse set of drug candidates. Toxicol Lett 188:98-103.
39. Pfuhler S, Kirst A, Aardema M, Banduhn N, Goebel C, Araki D, Costabel-Farkas M, Dufour E, Fautz R, Harvey J, et al. 2010. A tiered approach to the use of alternatives to animal testing for the safety assessment of cosmetics: genotoxicity. A COLIPA analysis. Regul Toxicol Pharmacol 57:315-324.
40. Rasmussen C, Gratz K, Liebel F, Southall M, Garay M, Bhattacharyya S, Simon N, Vander Zanden M, Van Winkle K, Pirnstill J, et al. 2010. The StrataTest[R] human skin model, a consistent in vitro alternative for toxicological testing. Toxicol In Vitro 24:2021-2029.
41. Ren X, Lim S, Smith MT, Zhang L. 2009. Werner syndrome protein, WRN, protects cells from DNA damage induced by the benzene metabolite hydroquinone. Toxicol Sci 107:367-375.
42. Ren X, Aleshin M, Jo WJ, Dills R, Kalman DA, Vulpe CD, Smith MT, Zhang L. 2011. Involvement of N-6 adenine-specific DNA methyltransferase 1 [N6AMT1] in arsenic biomethylation and its role in arsenic-induced toxicity. Environ Health Perspect 119:771-777.
43. Ren X, Ji Z, McHale CM, Yuh J, Bersonda J, Tang M, Smith MT, Zhang L. 2013. The impact of FANCD2 deficiency on formaldehyde-induced toxicity in human lymphoblastoid cell lines. Arch Toxicol 87:189-196.
44. Reus AA, Reisinger K, Downs TR, Carr CJ, Zeller A, Corvi R, Krul CA, Pfuhler S. 2013. Comet assay in reconstructed 3D human epidermal skin models-investigation of intra- and inter-laboratory reproducibility with coded chemicals. Mutagenesis 28:709-720.
45. Rich IN, Hall KM. 2005. Validation and development of a predictive paradigm for hemotoxicology using a multifunctional bioluminescence colony-forming proliferation assay. Toxicol Sci 87:427-441.
46. Ridpath JR, Nakamura A, Tano K, Luke AM, Sonoda E, Arakawa H, Buerstedde JM, Gillespie DA, Sale JE, Yamazoe M, et al. 2007. Cells deficient in the FANC/BRCA pathway are hypersensitive to plasma levels of formaldehyde. Cancer Res 67:11117-11122.
47. Riebeling C, Hayess K, Peters AK, Steemans M, Spielmann H, Luch A, Seiler AE. 2012. Assaying embryotoxicity in the test tube: current limitations of the embryonic stem cell test [EST] challenging its applicability domain. Crit Rev Toxicol 42:443-464.
48. Sison-Young RL, Kia R, Heslop J, Kelly L, Rowe C, Cross MJ, Kitteringham NR, Hanley N, Park BK, Goldring CE. 2012. Human pluripotent stem cells for modeling toxicity. Adv Pharmacol 63:207-256.
49. Snyder RD. 2000. Use of catalytic topoisomerase II inhibitors to probe mechanisms of chemical-induced clastogenicity in Chinese hamster V79 cells. Environ Mol Mutagen 35:13-21.
50. Snyder RD. 2007. Assessment of atypical DNA intercalating agents in biological and in silico systems. Mutat Res 623:72-82.
51. Snyder RD, Arnone MR. 2002. Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay. Mutat Res 503:21-35.
52. Snyder RD, Strekowski L. 1999. Enhancement of bleomycin-induced micronucleus formation in V79 cells as a rapid and sensitive screen for non-covalent DNA-binding compounds. Mutat Res 444:181-192.
53. Snyder RD, Ewing DE, Hendry LB. 2004. Evaluation of DNA intercalation potential of pharmaceuticals and other chemicals by cell-based and three-dimensional computational approaches. Environ Mol Mutagen 44:163-173.
54. Snyder RD, Holt PA, Maguire JM, Trent JO. 2013. Prediction of noncovalent Drug/DNA interaction using computational docking models: studies with over 1350 launched drugs. Environ Mol Mutagen 54:668-681.
55. Strekowski L, Wilson B. 2007. Noncovalent interactions with DNA: an overview. Mutat Res 623:3-13.
56. Yamanaka S. 2007. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 1:39-49.
57. Yamazoe M, Sonoda E, Hochegger H, Takeda S. 2004. Reverse genetic studies of the DNA damage response in the chicken B lymphocyte line DT40. DNA Repair [Amst] 3:1175-1185.
58. Yang H, Shi L, Wang BA, Liang D, Zhong C, Liu W, Nie Y, Liu J, Zhao J, Gao X, et al. 2012. Generation of genetically modified mice by oocyte injection of androgenetic haploid embryonic stem cells. Cell 149:605-617.
59. Zhang S, Teng Y. 2013. Powering mammalian genetic screens with mouse haploid embryonic stem cells. Mutat Res 741-742:44-50.